Darovasertib
Darovasertib (LXS196) is a potent, selective, and orally bioavailable inhibitor of protein kinase C (PKC), demonstrating high selectivity for PKCα and PKCθ over GSK3β. It is a valuable research tool for investigating PKC signaling in oncology, particularly in uveal melanoma models, both in vitro and in vivo.
Product Specifications
CAS Number
1874276-76-2
Product Name Alternative
Darovasertib, inhibit, LXS 196, LXS196, LXS-196, IDE 196, IDE196, IDE-196, Inhibitor, Protein kinase C, PKC
Field of Research
Epigenetics & Chromatin, Signal Transduction
Purity
≥95% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:4 mg/mL (8.47 mM) ; DMSO:16.67 mg/mL (35.28 mM)
Smiles
CC1 (N) CCN (CC1) c1cccnc1NC (=O) c1nc (cnc1N) -c1ncccc1C (F) (F) F
Molecular Formula
C22H23F3N8O
Molecular Weight
472.47
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS7024046-01 0.02 mg
Recombinant Helicobacter hepaticus NADH-quinone oxidoreductase subunit K (nuoK)
Sign In for Pricing
View Details MBS7024046-02 0.1 mg
Recombinant Helicobacter hepaticus NADH-quinone oxidoreductase subunit K (nuoK)
Sign In for Pricing
View Details MBS7024046-03 5x 0.1 mg
Recombinant Helicobacter hepaticus NADH-quinone oxidoreductase subunit K (nuoK)
Sign In for Pricing
View Details MBS6423914-01 0.1 mL
KIR2DL1 (Killer Cell Immunoglobulin Like Receptor 2DL1, NKAT, NKAT1, p58.1, CD158A, KIR221, KIR-K64) (FITC)
Sign In for Pricing
View Details MBS6423914-02 5x 0.1 mL
KIR2DL1 (Killer Cell Immunoglobulin Like Receptor 2DL1, NKAT, NKAT1, p58.1, CD158A, KIR221, KIR-K64) (FITC)
Sign In for Pricing
View Details